Innovative Cellular Therapeutics Holdings Ltd
10% Owner
- 2026
- Jul 28, 2026
- 6
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Innovative Cellular Therapeutics Holdings Ltd files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ARCH Venture Fund XIII, L.P. - $12.50M in LYEL purchases and sales in the last 12 months
- ARCH Venture Partners IX, LLC - $12.50M in LYEL purchases and sales in the last 12 months
- Lynn Seely - $353K in LYEL purchases and sales in the last 12 months
- Gary K. Lee - $72K in LYEL purchases and sales in the last 12 months
- Stephen J. Hill - $51K in LYEL purchases and sales in the last 12 months
- David Shook - $31K in LYEL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is Innovative Cellular Therapeutics Holdings Ltd?
Innovative Cellular Therapeutics Holdings Ltd is a corporate entity, tracked as 10% Owner of Lyell Immunopharma, Inc. (LYEL). InsiderAlpha holds 6 primary Form 4 filings for it, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Innovative Cellular Therapeutics Holdings Ltd submitted recently?
4 primary Form 4 filings in the last 90 days, covering 1 company.
Has Innovative Cellular Therapeutics Holdings Ltd been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($274) across all tracked filings.
